New York Post
13 Nov 2026, 18:42 UTC · 1h ago
Swiss dental startup vVardis shares slide 7% in NYSE debut as tech selloff roils IPO market
Impact · against what's priced in
vVardis is facing early market skepticism as its shares trade below the IPO price, reflecting investor concerns over high customer concentration and ongoing losses. While top-line growth for its flagship product is strong, the valuation is being pressured by a broader technology selloff and a cautious IPO environment.
- VARD−0.60
No priced-in read yet
- In context
Shares fell 7% in their NYSE debut, trading below $17 after pricing at $18—a minimum 14% discount to the target range—as investors react to ongoing losses and heavy reliance on a single customer.
Read from the article alone
Search tags
